The biotech industry and what interviews look for

The biotech industry spans drug discovery (identifying and validating biological targets), preclinical research (in vitro and in vivo studies), clinical development (Phase I-III trials), regulatory affairs (navigating approval processes with the MHRA, EMA, and FDA), and commercial functions (market access, sales, medical affairs). The UK biotech cluster is concentrated in the Cambridge (the Golden Triangle also includes Oxford and London), Edinburgh, and Manchester areas, with a strong network of spin-outs from university research. Interview expectations vary significantly by function and by company stage: an early-stage biotech will often expect scientists to be generalists comfortable spanning multiple functions; a large biotech like AstraZeneca or GSK will expect deep function-specific expertise.

Science interview questions in biotech

"Walk me through your thesis / PhD project." For any scientist entering the industry from academia, this is the centrepiece question. The best answers are: explained at a level appropriate to the interviewer's background (ask who will be in the interview so you can calibrate), focused on why the questions mattered and what you found, honest about what did not work and what you learned from it, and connected to how the skills transfer to an industry context. The most common mistake: spending all the time on technical background and not leaving enough time to explain what you actually found and what it means.

"How is drug discovery in industry different from academic research?" This tests whether candidates have thought beyond their academic experience. Key differences: industry research is goal-directed toward a specific therapeutic target and patient population; timelines and budgets are explicit constraints; failure at any stage is expected and built into portfolio management (most drug candidates fail); multi-disciplinary collaboration (between biology, chemistry, ADMET, clinical, regulatory, and commercial teams) is the norm; and intellectual property and confidentiality shape how science is communicated and published.

Commercial biotech interview questions

For market access, medical affairs, and business development roles: "How does HTA (Health Technology Assessment) affect a new drug's commercial launch in the UK?" NICE (National Institute for Health and Care Excellence) evaluates drugs for cost-effectiveness (the QALY threshold) and recommends whether the NHS should fund them. A positive NICE recommendation is critical for commercial uptake in England. Scotland (SMC), Wales (AWMSG), and Northern Ireland follow different processes. Understanding the relationship between clinical trial design, NICE submission, and commercial strategy is essential for any UK-focused market access or commercial role in biotech.

Get real-time help in your next interview
Live Interview Help listens to your interview and surfaces personalised answers in real time. Free 20-minute trial on Google Meet, Teams, and Zoom.
Install Free on Chrome

Frequently asked questions

Do I need a PhD to work in biotech?
It depends on the function. For discovery research (molecular biology, pharmacology, structural biology, chemistry), a PhD is typically expected at scientist level and above. For clinical operations, regulatory affairs, medical affairs, and business functions, a degree plus relevant experience is usually sufficient, and professional experience can carry more weight than a PhD in these areas. Data science and bioinformatics roles are an area where strong computational skills with an MSc can be competitive against PhD candidates, depending on the company and the specific role.
What is it like working at a UK biotech startup?
UK biotech startups (typically spin-outs from Cambridge, Oxford, or London universities, or founded by industry veterans) offer significant technical breadth, strong mission alignment, and direct impact on the research direction. The trade-offs: salaries at early-stage biotechs are often below large pharma, though equity can be significant if the company progresses; job security depends on funding; and resource constraints mean scientists often work across functions rather than specialising deeply. For scientists who want to see the direct commercial and clinical impact of their work and who thrive in a high-ownership environment, early-stage biotech can be more satisfying than large pharmaceutical research.